A phase 1 first-in-human study of the oral GLP-1 receptor agonist ECC5004/AZD5004 in healthy volunteers and T2DM patients found it well tolerated with early dose-dependent glucose and weight signals. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
A 6-month randomised trial in older adults with type 2 diabetes found home telemedicine plus Health Belief Model education cut HbA1c by 0.42% more than usual care. PICO summary and expert commentary.
An oral GLP-1 receptor agonist lowered HbA1c and body weight in phase 2 but was halted early after transaminase elevations ended its development. PICO summary and expert commentary.
A post-hoc EXSCEL analysis testing whether baseline ejection fraction modifies the effect of once-weekly exenatide on heart failure hospitalisation in type 2 diabetes. PICO summary and expert commentary.
A Sanofi-sponsored post hoc analysis of the LixiLan-L-CN trial reports that iGlarLixi lowered residual hyperglycaemia more than insulin glargine alone in Chinese adults with type 2 diabetes. PICO summary and expert commentary.
Exploratory analysis of AMPLITUDE-O finds baseline FIB-4 score is not associated with cardiovascular outcomes and does not modify efpeglenatide’s effect in high-risk type 2 diabetes. PICO summary and expert commentary.
The ARIADNE non-inferiority trial tested whether a supported total diet replacement programme worsened eating disorder symptoms in adults with type 2 diabetes at high risk. PICO summary and expert commentary.
A Phase 2 randomised trial in 145 adults found once-weekly ecnoglutide lowered HbA1c by up to 2.39% versus 0.55% with placebo over 20 weeks. PICO summary and expert commentary.
A SURMOUNT-2 subpopulation analysis of 41 Japanese adults with type 2 diabetes and obesity, in which once-weekly tirzepatide produced significant 72-week weight loss versus placebo, tempered by a very small sample. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN China asked whether baseline traits modify the glycaemic effect of once-weekly semaglutide versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.